Devyser Diagnostics
132.5
SEK
-0.38 %
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
2 following
-0.38%
-0.38%
+1.53%
+23.26%
+33.3%
+68.58%
+97.76%
-
-
+48.88%
investors.devyser.com/en
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Revenue
169.3M
EBIT %
-34.79 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DVYSR
Daily low / high price
132.5 / 135
SEK
Market cap
2.19B SEK
Turnover
375.44K SEK
Volume
2.8K
Latest videos
Financial calendar
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Rutger Arnhult, via bolag | 24.5 % | 24.5 % |
| Nordnet Pensionsförsäkringar | 10.6 % | 10.6 % |
| Swedbank Robur | 6.5 % | 6.5 % |
| Fjärde AP-fonden | 4.6 % | 4.6 % |
| Stockholm Pacific AB, Åsa Riisberg | 4.0 % | 4.0 % |
| Berenberg Asset Management på uppdrag av Universal Investment funds | 3.8 % | 3.8 % |
| Anders Hedrum, privat och via bolag | 2.5 % | 2.5 % |
| Deka Investements | 2.5 % | 2.5 % |
| Insr Insurance Group | 2.3 % | 2.3 % |
| Protean Funds | 2.2 % | 2.2 % |
ShowingAll content types
Valberedning utsedd inför årsstämman 2025 i Devyser Diagnostics AB
Nomination Committee Appointed Ahead of the 2025 Annual General Meeting in Devyser Diagnostics AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Redeye: Devyser Q3 - All eyes on Q4
